

Table S1. Correlation matrix of surrogate variables of tacrolimus exposure / metabolism at the time of the first biopsy. TAC-C₀ (ng/mL), tacrolimus trough levels; CV-TAC (%), coefficient of variability of tacrolimus levels; TTR (%), time in therapeutic range; above TR (%), time above therapeutic; below TR (%), time below therapeutic range; C/D (ng/mL/mg), concentration dose ratio.

	TAC-C ₀	CV-TAC	TTR	Above TR	Below TR	C/D
TAC-C ₀	1					
CV-TAC	-0.226 0.037	1				
TTR	-0.047 0.671	-0.476 <0.001	1			
Above TR	0.158 0.148	0.293 0.006	-0.863 <0.001	1		
Below TR	-0.215 0.049	0.338 0.002	-0.239 0.028	-0.285 0.008	1	
C/D	0.161 0.142	0.052 0.639	-0.265 0.014	0.311 0.004	-0.095 0.386	1

Table S2. Correlation matrix of surrogate variables of tacrolimus exposure / metabolism at the time of the second biopsy. TAC-C₀ (ng/mL), tacrolimus trough levels; CV-TAC (%), coefficient of variability of tacrolimus levels; TTR (%), time in therapeutic range; above TR (%), time above therapeutic; below TR (%), time below therapeutic range; C/D (ng/mL/mg), concentration dose ratio.

	TAC-C ₀	CV-TAC	TTR	Above TR	Below TR	C/D
TAC-C ₀	1					
CV-TAC	0.048 0.665	1				
TTR	-0.427 <0.001	-0.149 0.178	1			
Above TR	0.230 0.005	0.111 0.318	-0.792 <0.001	1		
Below TR	-0.222 0.041	0.229 0.037	-0.027 0.809	-0.304 0.005	1	
C/D	0.236 0.029	-0.006 0.955	-0.018 0.870	-0.005 0.962	-0.091 0.405	1

Table S3. Inflammation and tubulitis in areas of interstitial fibrosis / tubular atrophy in the first surveillance biopsy and surrogate variables of tacrolimus exposure / metabolism. TAC-C₀, tacrolimus trough levels; CV-TAC, coefficient of variability of tacrolimus levels; TTR, time in therapeutic range; above TR, time above therapeutic; below TR, time below therapeutic range; C/D, concentration dose ratio; i-IFTA, Interstitial inflammation in areas of interstitial fibrosis and tubular atrophy; t-IFTA, tubulitis in areas of interstitial fibrosis and tubular atrophy.

i-IFTA=0 & t-IFTA=0	i-IFTA ≥ 1 & t-IFTA=0	i-IFTA=0 & t-IFTA ≥ 1	t-IFTA	i-IFTA ≥ 1 or i-IFTA ≥ 1 & t-IFTA=1	i -IFTA ≥ 2 & t-IFTA ≥ 2	p-value
Normal	Inflammation w/o tubulitis	Tubulitis w/o inflammation		Borderline changes	Chronic TCMR	
N	31	27	1	24	2	
TAC-C ₀ (ng/mL)	10.0 ± 2.9	9.4 ± 2.1	9.2	9.4 ± 2.3	9.6 ± 1.1	0.8815
CV-TAC (%)	31 ± 12	30 ± 15	36	32 ± 12	33 ± 14	0.9712

TTR (%)	48 ± 18	63 ± 22	60	54 ± 22	78 ± 9	0.1123
Time above TR (%)	42 ± 18	31 ± 24	24	32 ± 21	20±9	0.3659
Time below TR (%)	10 ± 14	6 ± 8	16	14 ± 16	2± 0	0.1496
C/D (ng/mL/mg)	1.8 ± 1.3	2.2 ± 1.7	1.0	2.0± 1.4	1.7 ± 0	0.7546

Table S4. Inflammation and tubulitis in areas of interstitial fibrosis / tubular atrophy in the second surveillance biopsy and surrogate variables of tacrolimus exposure / metabolism. TAC-C₀, tacrolimus trough levels; CV-TAC, coefficient of variability of tacrolimus levels; TTR, time in therapeutic range; above TR, time above therapeutic; below TR, time below therapeutic range; C/D, concentration dose ratio; i-IFTA. Interstitial inflammation in areas of interstitial fibrosis and tubular atrophy; t-IFTA, tubulitis in areas of interstitial fibrosis and tubular atrophy.

	i-IFTA=0 & t-IFTA=0	i-IFTA ≥1 & t-IFTA=0	i-IFTA=0 & t-IFTA ≥1	t-IFTA ≥1 or i-IFTA≥1 & t-IFTA=1	i -IFTA≥2 & t-IFTA≥2	p-value
Normal	Inflammation w/o tubulitis	Tubulitis w/o inflammation		Borderline changes	Chronic TC MR	
N	26	23	2	29	5	
TAC-C ₀ (ng/mL)	8.6 ± 1.8	8.2 ± 2.0	6.7 ± 1.5	8.7 ± 2.9	8.0 ± 1.9	0.6952
CV-TAC (%)	18 ± 6	17 ± 7	22 ± 0	19 ± 8	21 ± 8	0.7380
TTR (%)	70 ± 27	63 ± 30	74 ± 37	62 ± 16	52 ± 25	0.4942
Time above TR (%)	29 ± 28	33 ± 32	26 ± 37	23 ± 27	41 ± 34	0.6598
Time below TR (%)	1 ± 3	6 ± 17	19 ± 28	4 ± 7	8 ± 13	0.1149
C/D (ng/mL/mg)	2.5 ± 1.1	2.1 ± 0.9	1.7 ± 0.8	1.9 ± 1.0	2.3 ± 0.9	0.1898